CIK 0000072444 · Accelerated filer<br>Smaller reporting company
Vaxart, Inc.
Sign in to watch- Ticker
- VXRT
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 591212264
- Phone
- (650) 550-3500
- Business address
- 310 UTAH AVENUE, SUITE 150, SOUTH SAN FRANCISCO, CA
- Former names
- Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., NABI BIOPHARMACEUTICALS, NABI BIOPHARMACEUTICALS, NABI /DE/, NORTH AMERICAN BIOLOGICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-11 | Watson W. Mark Director | Grant or award · Stock Option (right to buy) | +95,400 | 95,400 | ||
| 2024-06-11 | Yedid Robert A. Director | Grant or award | +16,000 | 34,490 | ||
| 2024-06-11 | Yedid Robert A. Director | Grant or award · Stock Option (right to buy) | +95,400 | 95,400 | ||
| 2024-03-28 | Tucker Sean SVP, Chief Scientific Officer | Shares withheld for taxes | −3,902 | $1.30 | $5K | 355,695 |
| 2024-03-28 | Cummings James F. Chief Medical Officer | Shares withheld for taxes | −3,292 | $1.30 | $4K | 326,801 |
| 2024-03-18 | Tucker Sean SVP, Chief Scientific Officer | Grant or award | +90,000 | 420,122 | ||
| 2024-03-18 | Tucker Sean SVP, Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +410,000 | 410,000 | ||
| 2024-03-18 | Lee Phillip E Chief Financial Officer | Grant or award | +90,000 | 241,808 | ||
| 2024-03-18 | Lee Phillip E Chief Financial Officer | Grant or award · Stock Option (right to buy) | +410,000 | 410,000 | ||
| 2024-03-18 | Cummings James F. Chief Medical Officer | Grant or award | +90,000 | 330,093 | ||
| 2024-03-18 | Cummings James F. Chief Medical Officer | Grant or award · Stock Option (right to buy) | +410,000 | 410,000 | ||
| 2024-03-18 | Berg Edward B SVP, General Counsel | Grant or award | +90,000 | 270,706 | ||
| 2024-03-18 | Berg Edward B SVP, General Counsel | Grant or award · Stock Option (right to buy) | +410,000 | 410,000 | ||
| 2024-03-18 | Lo Steven President, Chief Exec Officer | Grant or award | +250,000 | 250,000 | ||
| 2024-03-18 | Lo Steven President, Chief Exec Officer | Grant or award · Stock Option (right to buy) | +1,000,000 | 1,000,000 | ||
| 2024-02-02 | Tucker Sean SVP, Chief Scientific Officer | Shares withheld for taxes | −9,220 | $1.20 | $11K | 330,122 |
| 2024-02-02 | Cummings James F. Chief Medical Officer | Shares withheld for taxes | −7,965 | $1.20 | $10K | 240,093 |
| 2024-02-02 | Berg Edward B SVP, General Counsel | Shares withheld for taxes | −9,220 | $1.20 | $11K | 180,706 |
| 2023-12-15 | Lee Phillip E Chief Financial Officer | Shares withheld for taxes | −5,943 | $0.63 | $4K | 151,808 |
| 2023-12-08 | Tucker Sean SVP, Chief Scientific Officer | Shares withheld for taxes | −34,288 | $0.71 | $24K | 339,342 |
Page 6 of 10 · 198 trades